---
title: "Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285634757.md"
description: "Needham analyst Boris Peaker has reiterated a Buy rating on Enliven's ELVN stock, citing strong efficacy of ELVN-001 in chronic myeloid leukemia (CML) compared to existing therapies. He highlights significant early Phase 1 data and upcoming catalysts, including additional Phase 1 data in mid-2026 and the pivotal Phase 3 ENABLE-2 trial starting in late 2026. Peaker views Enliven as a strategic asset, especially after Merck's acquisition of a competitor, positioning it well for potential takeover opportunities. Clear Street also maintains a Buy rating with a $55 price target."
datetime: "2026-05-07T23:15:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285634757.md)
  - [en](https://longbridge.com/en/news/285634757.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285634757.md)
---

# Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway

JonesTrading analyst Boris Peaker has maintained their bullish stance on ELVN stock, giving a Buy rating on April 27.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Boris Peaker has given his Buy rating due to a combination of factors, primarily the strong clinical performance of ELVN-001 in chronic myeloid leukemia relative to existing therapies. Early Phase 1 data show major molecular response rates that substantially exceed current standard-of-care outcomes in later-line settings, suggesting a meaningful efficacy advantage that could translate into significant clinical uptake.

Peaker also highlights upcoming catalysts, including additional Phase 1 data in mid-2026 and the planned start of the pivotal Phase 3 ENABLE-2 trial in the second half of 2026, which together de-risk the development path. In addition, he views Enliven as an attractive strategic asset, noting Merck’s sizable acquisition of a key competitor as validation of the space and arguing that Enliven’s focused CML profile and promising data position it well for a potential future takeover.

In another report released on April 27, Clear Street also maintained a Buy rating on the stock with a $55.00 price target.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)